Table 2 Clinical characteristics and impacts of Pneumocystis jirovecii pneumonia on outcomes.

From: Comparison of early and late Pneumocystis jirovecii Pneumonia in kidney transplant patients: the Korean Organ Transplantation Registry (KOTRY) Study

 

Non-PJP (n = 4,789)

PJP (n = 50)

P value

Onset after transplantation (months)

 

8.4 ± 7.6

 

0–6 months -n (%)

 

25 (50.0%)

 

6–12 months -n (%)

 

15 (30.0%)

 

12–24 months -n (%)

 

8 (16.0%)

 

24–36 months -n (%)

 

1 (2.0%)

 

36–48 months -n (%)

 

1 (2.0%)

 

Graft rejection before PJP -n (%)

N/A

13 (26.0%)

 

Time from rejection to PJP (months)

N/A

5.9 ± 3.6

 

CMV infection before PJP -n (%)

N/A

1 (2.0%)

 

Graft loss

103 (2.2%)

4 (8.0%)

0.024

Death

75 (1.6%)

9 (18.0%)

 < 0.001

Death due to PJP

N/A

7 (14.0%)

 
  1. Note: data are presented as mean ± standard deviation, or n (%).
  2. Abbreviations: CMV, cytomegalovirus; N/A, not applicable; PJP, pneumocystis jirovecii pneumonia.
Back to article page